Literature DB >> 23251849

Genetic and Prognostic Differences of Non-small Cell Lung Cancer between Elderly Patients and Younger Counterparts.

Kenichi Suda1, Kenji Tomizawa, Hiroshi Mizuuchi, Simon Ito, Hirokazu Kitahara, Shinichiro Shimamatsu, Mikihiro Kohno, Tsukihisa Yoshida, Tatsuro Okamoto, Yoshihiko Maehara, Yasushi Yatabe, Tetsuya Mitsudomi.   

Abstract

Many elderly patients suffer from lung cancers, but it is not clear if their lung cancers differ from those of younger patients. In this study, we compared genetic and prognostic characteristics of lung cancers of patients aged ≥75 years with those of patients aged ≤ 64 years. In the genetic analysis, we explored 292 surgically treated non-squamous cell lung cancers with known mutational status of epidermal growth factor (EGFR) and anaplastic lymphoma kinase (ALK). In the prognostic analysis, we retrospectively analyzed 405 surgically treated non-small cell lung cancers (NSCLCs) before the era of routine clinical application of post-surgical adjuvant chemotherapy. Postsurgical recurrence-free survival (RFS) was compared between elderly patients and younger counterparts. The genetic analysis showed elderly non-squamous cell lung cancer patients to have higher prevalence of EGFR mutations (53.1 % vs 42.0%, P = 0.15) and lower prevalence of the ALK translocation (0 % vs 4.5%, P = 0.23) than their younger counterparts. The prognostic analysis showed postsurgical RFS was similar between the elderly NSCLC patients and the younger patients. However in multivariate analysis, adjusting for gender, smoking status, pathological stage, and histology, elderly patients had significantly worse prognoses (HR 1.57, 95% CI, 1.08-2.29; P = 0.02) compared with younger patients. These results suggest differences in genetic and prognostic aspects between elderly lung cancer patients and younger lung cancer patients.

Entities:  

Keywords:  Oncogenic driver mutation; anaplastic lymphoma kinase translocation; epidermal growth factor receptor gene mutation; prognostic factor; recurrence-free survival

Year:  2012        PMID: 23251849      PMCID: PMC3522510     

Source DB:  PubMed          Journal:  Aging Dis        ISSN: 2152-5250            Impact factor:   6.745


  18 in total

1.  Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.

Authors:  Yang Zhang; Yihua Sun; Yunjian Pan; Chenguang Li; Lei Shen; Yuan Li; Xiaoyang Luo; Ting Ye; Rui Wang; Haichuan Hu; Hang Li; Lei Wang; William Pao; Haiquan Chen
Journal:  Clin Cancer Res       Date:  2012-02-08       Impact factor: 12.531

2.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

3.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

4.  Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.

Authors:  Jin Ho Paik; Chang-Min Choi; Hyojin Kim; Se Jin Jang; Gheeyoung Choe; Dong Kwan Kim; Hwa Jung Kim; Hoil Yoon; Choon-Taek Lee; Sanghoon Jheon; Ji-Young Choe; Jin-Haeng Chung
Journal:  Lung Cancer       Date:  2011-11-30       Impact factor: 5.705

5.  Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.

Authors:  Rebecca Siegel; Elizabeth Ward; Otis Brawley; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2011-06-17       Impact factor: 508.702

6.  Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project.

Authors:  Tomohiro Matsuda; Tomomi Marugame; Ken-Ichi Kamo; Kota Katanoda; Wakiko Ajiki; Tomotaka Sobue
Journal:  Jpn J Clin Oncol       Date:  2011-12-15       Impact factor: 3.019

Review 7.  Chemotherapy in elderly patients with advanced non-small cell lung cancer.

Authors:  Elisabeth Quoix; Virginie Westeel; Gérard Zalcman; Bernard Milleron
Journal:  Lung Cancer       Date:  2011-09-03       Impact factor: 5.705

8.  EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

Authors:  Kentaro Inamura; Kengo Takeuchi; Yuki Togashi; Satoko Hatano; Hironori Ninomiya; Noriko Motoi; Ming-yon Mun; Yukinori Sakao; Sakae Okumura; Ken Nakagawa; Manabu Soda; Young Lim Choi; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Mod Pathol       Date:  2009-02-20       Impact factor: 7.842

9.  Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.

Authors:  Takayuki Kosaka; Yasushi Yatabe; Ryoichi Onozato; Hiroyuki Kuwano; Tetsuya Mitsudomi
Journal:  J Thorac Oncol       Date:  2009-01       Impact factor: 15.609

10.  Prognostic effect of age on survival of patients with stage I adenocarcinoma of the lung.

Authors:  Jeong-Seon Ryu; Chang-Min Choi; Seok-Chul Yang; Sang-Yun Song; Young-June Jeon; Tae-Won Jang; Do-Jin Kim; Seung Hun Jang; Sei-Hoon Yang; Min-Ki Lee; Kwan-Ho Lee; Hyang-Jeong Jo; Se-Jin Jang; Young-Tae Kim; Jae-Hwa Cho; Yoo-Duk Choi; Hae-Seong Nam; Hyun-Jung Kim; Young Ju Suh
Journal:  Tumori       Date:  2012 Jan-Feb
View more
  3 in total

1.  Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma.

Authors:  Hong Tao; Yiran Cai; Liang Shi; Junfang Tang; Zhidong Liu; Zitong Wang; Lianqi Bai; Zhe Liu
Journal:  Thorac Cancer       Date:  2016-10-24       Impact factor: 3.500

2.  Ophiopogon Saponin C1 Inhibits Lung Tumors by Stabilizing Endothelium Permeability via Inhibition of PKCδ.

Authors:  Yuanyuan Zhang; Yazheng Zhao; Yan Wu; Jin Qi; Fang Li; Junping Kou; Boyang Yu
Journal:  Int J Biol Sci       Date:  2020-01-01       Impact factor: 6.580

3.  Non-small cell lung cancer therapy: safety and efficacy in the elderly.

Authors:  Owen S Glotzer; Thomas Fabian; Anurag Chandra; Charles T Bakhos
Journal:  Drug Healthc Patient Saf       Date:  2013-04-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.